Lack of Indinavir Effects on Methadone Disposition Despite Inhibition of Hepatic and Intestinal Cytochrome P4503A (CYP3A)
Open Access
- 1 February 2012
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 116 (2) , 432-447
Abstract
Background: Methadone disposition and pharmacodynamics are highly susceptible to interactions with antiretroviral drugs. Methadone clearance and drug interactions have been attributed to cytochrome P4503A4 (CYP3A4), but actual mechanisms are unknown. Drug interactions can be clinically and mechanistically informative. This investigation assessed effects of the protease inhibitor indinavir on methadone pharmacokinetics and pharmacodynamics, hepatic and intestinal CYP3A4/5 activity (using alfentanil), and intestinal transporter activity (using fexofenadine). Methods: Twelve healthy volunteers underwent a sequential crossover. On three consecutive days they received oral alfentanil plus fexofenadine, intravenous alfentanil, and intravenous plus oral (deuterium-labeled) methadone. This was repeated after 2 weeks of indinavir. Plasma and urine analytes were measured by mass spectrometry. Opioid effects were measured by miosis. Results: Indinavir significantly inhibited hepatic and first-pass CYP3A activity. Intravenous alfentanil systemic clearance and hepatic extraction were reduced to 40-50% of control, apparent oral clearance to 30% of control, and intestinal extraction decreased by half, indicating 50% and 70% inhibition of hepatic and first-pass CYP3A activity. Indinavir increased fexofenadine area under the plasma concentration-time curve 3-fold, suggesting significant P-glycoprotein inhibition. Indinavir had no significant effects on methadone plasma concentrations, methadone N-demethylation, systemic or apparent oral clearance, renal clearance, hepatic extraction or clearance, or bioavailability. Methadone plasma concentration-effect relationships were unaffected by indinavir. Conclusions: Despite significant inhibition of hepatic and intestinal CYP3A activity, indinavir had no effect on methadone N-demethylation and clearance, suggesting little or no role for CYP3A in clinical disposition of single-dose methadone. Inhibition of gastrointestinal transporter activity had no influence of methadone bioavailability.Keywords
This publication has 76 references indexed in Scilit:
- Mechanism of Efavirenz Influence on Methadone Pharmacokinetics and PharmacodynamicsClinical Pharmacology & Therapeutics, 2012
- Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependenceThe American Journal of Drug and Alcohol Abuse, 2011
- Impact of Ignoring Extraction Ratio When Predicting Drug-Drug Interactions, Fraction Metabolized, and Intestinal First-Pass ContributionDrug Metabolism and Disposition, 2010
- Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer PainThe Journal of Pain, 2009
- Role of CYP3A5 in Abnormal Clearance of MethadoneAnnals of Pharmacotherapy, 2008
- In Vivo Activation of Human Pregnane X Receptor Tightens the Blood-Brain Barrier to Methadone through P-Glycoprotein Up-RegulationMolecular Pharmacology, 2006
- Methadone—metabolism, pharmacokinetics and interactionsPharmacological Research, 2004
- No clinically significant pharmacokinetic interactions between voriconazole and indinavir in healthy volunteersBritish Journal of Clinical Pharmacology, 2003
- The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activityClinical Pharmacology & Therapeutics, 2003
- Enzymes in addition to CYP3A4 and 3A5 mediateN-demethylation of dextromethorphan in human liver microsomesBiopharmaceutics & Drug Disposition, 1999